GTBP: Phase I trials for TriKE therapies show early promise, with key data readouts expected soon
The TriKE platform is advancing in phase I trials for both blood cancers and solid tumors, showing promising early safety and efficacy signals. The technology's modular design enables rapid adaptation to new targets, with upcoming milestones including key data readouts and expansion into autoimmune…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.